Video
22 Oct 2021

How is M&A Shifting the Pharma Manufacturing Landscape?

Watch Video

Innovative manufacturing technologies are creating fresh deal-making opportunities for Pharma Manufacturers and CDMOs across both small and large molecule sectors, which are in turn transforming the pharma manufacturing landscape. Partnerships and mergers are a key tool for adding value to pharmaceutical companies; helping to navigate technological limitations, address portfolio challenges and chase innovation. This webinar, delivered in partnership with PharmaVentures, examines the trends and developments driving deal-making in the current market. Chaired by Dr Fintan Walton, CEO & Founder of PharmaVentures, the panel included: John P. FitzGerald, Senior Director, Business Development & Acquisitions, Abbvie Andreas Raabe, Managing Partner & Founder, Adragos Pharma William S. Marth, Managing Partner, North Ocean Ventures Jansen Jacob, Vice President, PharmaVentures Ozgur Akbulut, Director – Global Divestments and Contract Manufacturing Lead, Takeda

Read more Show less
Content provided by our supplier

PHARMAVENTURES LTD

  • GB
  • 2020
    On CPHI since
  • 25 - 49
    Employees
Company types
Consultancy
View company profile

Other Content from PHARMAVENTURES LTD (10)

  • Size doesn’t matter: How smaller deals are shaping healthcare M&A

    Sponsored Content Size doesn’t matter: How smaller deals are shaping healthcare M&A

    Several mega-deals have made a splash in the pharma and life sciences industries over recent years – from AstraZeneca’s acquisition of Alexion for $39 billion to Gilead Sciences’ $21 billion purchase of Immunomedics. With ample capital available in the sector, it comes as no surprise that PwC forecasts M&A deals will reach $400 billion this year.  
    12 Apr 2022
  • PharmaVentures Corporate Brochure

    Brochure PharmaVentures Corporate Brochure

    Download PharmaVentures' Corporate Brochure. 
  • Termsheet Issue 33

    Technical Data Termsheet Issue 33

    Vaccines, patents and supply. 
  • Deal Making in the Year of COVID-19

    Whitepaper Deal Making in the Year of COVID-19

    In the Spring of 2020, during the early days of the COVID-19 pandemic when there were real fears of a global downturn, PharmaVentures predicted that despite the forthcoming challenges, licensing and partnering would remain steady during 2020. With the year behind us, we are revisiting our deal closing predictions to see if they have held true.
  • M&A in COVID-19 environment and beyond Keep your perspective

    Whitepaper M&A in COVID-19 environment and beyond Keep your perspective

    As you are aware PharmaVentures is a sector focused advisory firm and we are at the forefront of deal-making activity in the pharmaceutical, biotech, medtech and service sector industries such as CROs and CDMOs. Given the current backdrop and challenges facing companies executing live transactions or contemplating entering acquisition or divestment processes, we thought it may be useful to share with you our thoughts on the current deal-making environment and what we see in the ‘trenches’ of ongoing processes for our clients. 
  • Is Nationalism Transforming the Pharma Manufacturing Map?

    Whitepaper Is Nationalism Transforming the Pharma Manufacturing Map?

    The last few years have seen a rise in nationalism and populism across the world. In 2016, the US voted in the populist Donald Trump on his promise to ‘Make America Great Again’. In 2018, Hungary re-elected its national conservative prime minister Viktor Orbán with the slogan ‘ For us, Hungary is first’. And in 2019, India re-elected its Hindu nationalist ruler, Nehendra Modi, and the UK elected (with a large majority) the Eurosceptic Boris Johnson on his pledge to ‘Get Brexit Done’. Other nationalist world leaders retaining their support base include Binyamin Netanyahu in Israel, and Rodrigo Duerte in the Philippines.
  • The Divestment Challenge

    Video The Divestment Challenge

    In this special edition of PharmaVentures Insights, we explore the challenges faced by pharmaceutical companies during the manufacturing divestment process, and how to accelerate the divestment process to achieve a successful outcome.
  • Contract Manufacturing in the Pharmaceutical Industry - Recipharm:

    Video Contract Manufacturing in the Pharmaceutical Industry - Recipharm:

    In this exclusive interview, Fintan Walton, CEO of PharmaVentures, speaks with Marc Funk, the new CEO of Recipharm.
  • Doing deals in the healthcare sector during the Covid-19 pandemic

    Video Doing deals in the healthcare sector during the Covid-19 pandemic

    The Chief Executive of PharmaVentures, a leading global corporate advisory firm in healthcare licensing, M&A and fundraising discusses how the current pandemic of 2020 will define the winners and losers in biopharmaceuticals.
  • What is Driving Consolidation in the Pharmaceutical Contract Services Industry

    Video What is Driving Consolidation in the Pharmaceutical Contract Services Industry

    This session was originally broadcast as part of the CPHI Worldwide 2021 digital content programme. This webinar focuses on the future of broader outsourced contract services in the Pharmaceutical Industry, which spans the Contract Development Manufacturing Sector (primary and secondary) that includes specialised biologics, excipients, fine chemicals and drug delivery, through to clinical research organisations, contract sales and more advisory based service offerings such as CMC and regulatory affairs. The webinar asks what is behind the consolidation activity and how sustainable is it? What’s shaping the future of the outsourcing industry? Will it remain fragmented or more consolidated? What is the outcome for the pharmaceutical industry? To what extent is private equity investment changing the outsourcing services business? What will the pharmaceutical services industry look like in 5 years?